H. Lundbeck A/S (HLUN-A.CO) Stock
H. Lundbeck A/S

Company profile
H. Lundbeck A/S reported revenue of 24.63 billion DKK for fiscal year 2025, up 11.9% from fiscal year 2024, and net income of 3.19 billion DKK. That is a net profit margin of 13.0% for fiscal year 2025. Our analysis of its filings shows revenue growing from 19.91 billion DKK in fiscal year 2023 to 24.63 billion DKK in fiscal year 2025, 11.2% a year on average. H. Lundbeck A/S reports about 5,000 full-time employees.
What stands out
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Leadership
- Charl van Zyl — President & CEO, 58
- Joerg Hornstein — CFO & Executive VP of Corporate Functions, 48
- Tarek Samad Ph.D. — Executive VP and Head of Research & Development
- Dianne Holto — Executive Vice President of People, Culture & Sustainability, 52
- Thomas E. Gibbs — Executive VP & Head of Lundbeck in United States, 54
In the news
- Avadel (AVDL) Gets 26% Boost on Takeover Bid
- Avadel (AVDL) Soars to 10-Year High on Brewing Bidding War
- Assessing Lundbeck Stock After Strong Three Year Rally and Steady Pharma Growth in 2025
- United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
How much revenue does H. Lundbeck A/S make?
H. Lundbeck A/S reported 24.63 billion DKK in revenue for fiscal year 2025, up 11.9% from 22.00 billion DKK in fiscal year 2024.
How has H. Lundbeck A/S's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 16.30 billion DKK; FY2022, 18.25 billion DKK; FY2023, 19.91 billion DKK; FY2024, 22.00 billion DKK; FY2025, 24.63 billion DKK.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “H. Lundbeck A/S (HLUN-A.CO)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/HLUN-A.CO